PL1773999T3 - Szczepionka do profilaktyki i leczenia zakażenia HIV - Google Patents

Szczepionka do profilaktyki i leczenia zakażenia HIV

Info

Publication number
PL1773999T3
PL1773999T3 PL05769948T PL05769948T PL1773999T3 PL 1773999 T3 PL1773999 T3 PL 1773999T3 PL 05769948 T PL05769948 T PL 05769948T PL 05769948 T PL05769948 T PL 05769948T PL 1773999 T3 PL1773999 T3 PL 1773999T3
Authority
PL
Poland
Prior art keywords
vaccine
hiv
infection
prevention
treatment
Prior art date
Application number
PL05769948T
Other languages
English (en)
Inventor
Helge Abrecht
Martine Delchambre
Martine Marchand
Nathalie Louise Mathy
Philippe Jean Gervais Ghislain Permanne
Gerald Hermann Voss
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of PL1773999T3 publication Critical patent/PL1773999T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05769948T 2004-08-05 2005-08-03 Szczepionka do profilaktyki i leczenia zakażenia HIV PL1773999T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0417494.2A GB0417494D0 (en) 2004-08-05 2004-08-05 Vaccine
EP05769948A EP1773999B1 (en) 2004-08-05 2005-08-03 Vaccine for prevention and treatment of hiv-infection
PCT/EP2005/008434 WO2006013106A2 (en) 2004-08-05 2005-08-03 Vaccine for prevention and treatment of hiv-infection

Publications (1)

Publication Number Publication Date
PL1773999T3 true PL1773999T3 (pl) 2010-02-26

Family

ID=32982606

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05769948T PL1773999T3 (pl) 2004-08-05 2005-08-03 Szczepionka do profilaktyki i leczenia zakażenia HIV

Country Status (31)

Country Link
US (2) US7612173B2 (pl)
EP (3) EP2130921B1 (pl)
JP (3) JP2008507987A (pl)
KR (1) KR101501495B1 (pl)
CN (2) CN101035897B (pl)
AR (2) AR050102A1 (pl)
AT (1) ATE443769T1 (pl)
AU (1) AU2005268856B2 (pl)
BR (1) BRPI0514108A (pl)
CA (1) CA2575898C (pl)
CY (1) CY1109667T1 (pl)
DE (1) DE602005016810D1 (pl)
DK (1) DK1773999T3 (pl)
ES (3) ES2334044T3 (pl)
GB (1) GB0417494D0 (pl)
HR (1) HRP20090678T1 (pl)
IL (2) IL180947A0 (pl)
MA (1) MA28983B1 (pl)
MX (1) MX2007001515A (pl)
MY (1) MY145614A (pl)
NO (1) NO20070988L (pl)
NZ (1) NZ552976A (pl)
PE (1) PE20060577A1 (pl)
PL (1) PL1773999T3 (pl)
PT (1) PT1773999E (pl)
RU (1) RU2441878C2 (pl)
SG (1) SG155206A1 (pl)
SI (1) SI1773999T1 (pl)
TW (1) TWI365191B (pl)
WO (1) WO2006013106A2 (pl)
ZA (1) ZA200700771B (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
CN1192766C (zh) * 1998-10-23 2005-03-16 伊迪亚股份公司 开发、测试和使用用于改进的有效负载和可控制性解缔/缔合速度的大分子和复合聚集体的缔合物的方法
SI1031346T1 (en) 1999-01-27 2002-08-31 Idea Ag Noninvasive vaccination through the skin
ES2173679T3 (es) 1999-01-27 2002-10-16 Idea Ag Inmunizacion/transporte transnasal con vehiculos altamente adaptables.
MXPA02000053A (es) * 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
CA2584475A1 (en) * 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions
BRPI0608798A2 (pt) * 2005-05-12 2011-03-15 Glaxo Group Ltd vetor de adenovìrus, composição imunogênica, uso de um vetor de adenovìrus, método para preparar um vetor, uso de um vetor de vìrus e um carreador ou adjuvante farmaceuticamente aceitável, e, proteìna de fusão
EP1885186B1 (en) * 2005-06-01 2015-09-02 California Institute Of Technology Method of targeted gene delivery using viral vectors
CA2651764A1 (en) * 2006-05-09 2007-11-22 Gerald V. Quinnan Hiv-1 immunogenic compositions
AU2007275010B2 (en) 2006-07-21 2013-06-20 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination
HUE031411T2 (en) * 2007-03-02 2017-07-28 Glaxosmithkline Biologicals Sa New Methods and Preparations
US9717788B2 (en) * 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
WO2008109785A2 (en) * 2007-03-06 2008-09-12 Rutgers, The State University Hiv reverse transcriptase compositions and methods
WO2008118936A2 (en) * 2007-03-26 2008-10-02 International Aids Vaccine Initiative Method of elicting immune response with a modified mva viral hiv-1 vector
CA2687632C (en) 2007-05-24 2013-01-15 Glaxosmithkline Biologicals S.A. Lyophilised antigen composition
EA201000829A1 (ru) * 2007-12-21 2011-06-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
RU2539765C2 (ru) 2008-07-16 2015-01-27 Бейлор Рисёч Инститьют ВИЧ ВАКЦИНА, ОСНОВАННАЯ НА НАПРАВЛЕННОСТИ МАКСИМИЗИРОВАННЫХ Gag И Nef НА ДЕНДРИТНЫЕ КЛЕТКИ
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
WO2010029562A1 (en) 2008-09-09 2010-03-18 Mukesh Harilal Shukla Bioactive composition for the treatment of the hiv/aids, method for manufacturing and using the same
HRP20140327T4 (hr) 2009-07-24 2017-11-03 Immune Design Corp Lentiviralni vektori pseudotipizirani sa glikoproteinom ovojnice virusa sindbis
AU2011231574A1 (en) 2010-03-26 2012-10-11 Glaxosmithkline Biologicals S.A. HIV vaccine
CN107641151B (zh) 2010-05-14 2021-10-01 百深公司 Ospa嵌合体及其在疫苗中的用途
US20130280322A1 (en) 2010-09-27 2013-10-24 Glaxosmithkline Biologicals S.A. Vaccine
JP2012120506A (ja) * 2010-12-10 2012-06-28 Tosoh Corp Ａｍｖ逆転写酵素遺伝子、該遺伝子によりコードされるａｍｖ逆転写酵素及び該遺伝子を用いるａｍｖ逆転写酵素の製造方法
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
JP2013146235A (ja) * 2012-01-20 2013-08-01 Tosoh Corp トリ骨髄芽細胞腫ウイルス逆転写酵素の製造方法
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
JP2015512263A (ja) 2012-03-30 2015-04-27 イミューン デザイン コーポレイション Ｄｃ−ｓｉｇｎを発現する細胞に対して改善された形質導入の有効性を有するレンチウイルスベクター粒子
US9782473B2 (en) 2013-03-26 2017-10-10 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
EP4140485A1 (en) 2014-07-11 2023-03-01 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
KR102014518B1 (ko) 2017-01-05 2019-08-26 서울대학교산학협력단 HIV 1의 p24 단백질을 발현하는 벡터가 도입된 재조합 마이코박테리움 스메그마티스 균주 및 이를 포함하는 백신
GB201812647D0 (en) 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer
CA3145791A1 (en) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines
WO2021195286A1 (en) 2020-03-27 2021-09-30 Svenska Vaccinfabriken Produktion Ab Compositions and methods for treating and preventing coronaviruses
KR20230131481A (ko) 2021-01-14 2023-09-13 길리애드 사이언시즈, 인코포레이티드 Hiv 백신 및 이의 사용 방법
WO2023056284A1 (en) 2021-09-29 2023-04-06 Svenska Vaccinfabriken Produktion Ab Compositions and methods for treating and preventing coronavirus infection

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
DE3300234A1 (de) 1983-01-05 1984-07-05 Display-Design GmbH für moderne Verkaufsförderungsmittel und Raumaussstattung, 6233 Kelkheim Etagenturm zur warenausstellung
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
DK643188A (da) * 1987-11-24 1989-05-25 Smithkline Biolog Ekspression af hiv-proteiner i e.coli og s.cerevisiae
US5221610A (en) 1988-05-26 1993-06-22 Institut Pasteur Diagnostic method and composition for early detection of HIV infection
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
ZA929870B (en) 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
KR0172970B1 (ko) 1992-06-17 1999-02-01 김영길 Aids백신에 유용한 키메릭 단백 및 그의 제조방법
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
EP0689454B2 (en) 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
DE69434151D1 (de) 1993-05-18 2004-12-30 Biomolecular Res Inst Ltd Therapeutische inhaltsstoffe
ES2149340T3 (es) 1993-11-17 2000-11-01 Om Pharma Disacaridos de glucosamina, metodo para su preparacion, composicion farmaceutica que los comprende, y su uso.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DE69535905D1 (de) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
AU4255397A (en) 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
EP0930893B1 (en) 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
WO1999010008A1 (en) 1997-08-29 1999-03-04 Aquila Biopharmaceuticals, Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
EP1104310B1 (en) 1998-08-04 2009-07-01 The Henry M. Jackson Foundation for the advancement of Military Medicine, Inc. Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response
EP1242441A4 (en) 1999-12-17 2004-04-14 Merck & Co Inc CODON OPTIMIZED HIV-1 NEF AND MODIFIED HIV-1 NEF EXPRESSING POLYNUCLEOTID VACCINE
DE60043856D1 (de) * 1999-12-23 2010-04-01 Medical Res Council Verbesserungen in oder in bezug auf immunantworten gegen hiv
US20020155127A1 (en) * 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
EP1320621A4 (en) 2000-09-15 2005-11-23 Merck & Co Inc IMPROVED ADENOVIRAL VACCINES OF THE FIRST GENERATION FOR THE EXPRESSION OF CODON-OPTIMIZED HIV-1 GAG, POL, NEF AND MODIFICATIONS (25.03.02)
CU23235A1 (es) * 2001-02-28 2007-09-26 Ct Ingenieria Genetica Biotech POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
AU2002327338A1 (en) * 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
CN100392085C (zh) * 2001-09-20 2008-06-04 葛兰素集团有限公司 疫苗
HU230364B1 (hu) 2001-11-21 2016-03-29 The Trustees Of The University Of Pennsylvania Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
AU2002360429A1 (en) 2001-11-26 2003-06-10 Avigen, Inc. Methods for producing stocks of recombinant aav virions
US20050266024A1 (en) * 2002-03-19 2005-12-01 Powdermed Limited Adjuvant
US20030190308A1 (en) * 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
CA2487831A1 (en) * 2002-06-11 2003-12-18 Glaxosmithkline Biologicals S.A. Immunogenic compositions
GB0225788D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US7501503B2 (en) * 2002-12-31 2009-03-10 Mcgill University Compositions and methods for inhibiting RNase H activity of retroid reverse transcriptase
CA2539864A1 (en) 2003-09-24 2005-04-07 Oxxon Therapeutics Limited Hiv pharmaccines
US20050175627A1 (en) 2003-09-24 2005-08-11 Oxxon Therapeutics Ltd. HIV pharmaccines

Also Published As

Publication number Publication date
EP2130921A3 (en) 2010-03-03
EP1773999B1 (en) 2009-09-23
KR101501495B1 (ko) 2015-03-11
ES2486669T3 (es) 2014-08-19
SI1773999T1 (sl) 2010-01-29
EP2130921A2 (en) 2009-12-09
AU2005268856B2 (en) 2012-05-24
MA28983B1 (fr) 2007-11-01
ES2334044T3 (es) 2010-03-04
US7612173B2 (en) 2009-11-03
JP2008507987A (ja) 2008-03-21
WO2006013106A3 (en) 2006-08-17
AR080216A2 (es) 2012-03-21
CN101035897A (zh) 2007-09-12
ES2445453T3 (es) 2014-03-03
RU2007104088A (ru) 2008-09-10
AR050102A1 (es) 2006-09-27
EP2130921B1 (en) 2013-11-20
US20070243203A1 (en) 2007-10-18
MY145614A (en) 2012-03-15
TWI365191B (en) 2012-06-01
EP2280073A3 (en) 2011-06-29
MX2007001515A (es) 2007-09-07
CN101035897B (zh) 2012-02-01
EP2280073B1 (en) 2014-06-11
KR20070041765A (ko) 2007-04-19
PT1773999E (pt) 2009-12-16
HRP20090678T1 (hr) 2010-01-31
GB0417494D0 (en) 2004-09-08
ATE443769T1 (de) 2009-10-15
CY1109667T1 (el) 2014-08-13
BRPI0514108A (pt) 2008-05-27
EP1773999A2 (en) 2007-04-18
AU2005268856A1 (en) 2006-02-09
JP2011234722A (ja) 2011-11-24
DK1773999T3 (da) 2010-01-18
IL207575A0 (en) 2011-07-31
DE602005016810D1 (de) 2009-11-05
WO2006013106A2 (en) 2006-02-09
EP2280073A2 (en) 2011-02-02
JP2014239687A (ja) 2014-12-25
JP6007212B2 (ja) 2016-10-12
NZ552976A (en) 2010-01-29
JP5629647B2 (ja) 2014-11-26
HK1108168A1 (en) 2008-05-02
NO20070988L (no) 2007-05-04
PE20060577A1 (es) 2006-08-07
CA2575898A1 (en) 2006-02-09
ZA200700771B (en) 2009-04-29
CN102633866A (zh) 2012-08-15
SG155206A1 (en) 2009-09-30
CA2575898C (en) 2015-09-29
US20100184836A1 (en) 2010-07-22
TW200621806A (en) 2006-07-01
CN102633866B (zh) 2015-04-15
RU2441878C2 (ru) 2012-02-10
IL180947A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
ZA200700771B (en) Vaccine for prevention and treatment of HIV-infection
SI1793855T1 (sl) Preventiva in zdravljenje sinukleinopatske in amiloidogene bolezni
AU2003290548A8 (en) Prevention and treatment of synucleinopathic disease
IL177914A0 (en) Use of indazolecarboxamide derivatives for the preparation of a medicament that is intended for the treatment and prevention of paludism
IL181896A0 (en) Methods and compositions for the treatment of hyperlipidemia
IL190478A0 (en) Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
ZA200709727B (en) Compounds and methods for the treatment of prevention of flavivirus infections
EP1618185A4 (en) NEW IMMUNOLOGICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCOULAR DISEASE
IL182436A0 (en) Thienopyridinone compounds and methods of treatment
IL178996A0 (en) Thienopyridinone compounds and methods of treatment
GB0610350D0 (en) prevention and/or treatment of neuodegenerative disorders
IL187405A0 (en) Methods and compositions for the treatment of pain
ZA200703087B (en) Methods and compositions for the treatment of hyperlipidemia
ZA200701531B (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
EP1814567A4 (en) USE OF MODULATORS OF EPHA2 AND EPHRINA1 FOR TREATING AND PREVENTING INFECTIONS
GB2441094B (en) Methods for treatment and prevention of infection
SI1812797T1 (sl) Pripravki in metode zdravljenja ter preprečevanja hiperprolifetarivnih bolezni
GB201010682D0 (en) Methods for treatment and prevention of infection
GB0510257D0 (en) Methods for treatment and prevention of infection
ZA200710476B (en) Methods and compositions for the treatment of pain
GB0612749D0 (en) Treatment and/or prevention of pain
GB0313065D0 (en) Vaccine and therapeutic treatment
KR100531650B1 (ko) 아프리카산 상황버섯 추출물을 함유하는 감기의 치료 및예방을 위한 약학조성물
GB0414428D0 (en) Compounds and methods of treatment
GB0415267D0 (en) The treatment of pain